We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Fetus Exposed to Radiation Has Increased Risk of Testicular Cancer

By HospiMedica International staff writers
Posted on 08 Mar 2012
Male fetuses of mothers that are exposed to radiation during early pregnancy may have an increased chance of developing testicular cancer, according to recent study in lab mice.

The article was published February 15, 2012, in the journal PLoS ONE. The study is the first to find an environmental cause for testicular germ cell tumors, the most common cancer in young Caucasian men. More...
“This discovery launches a major shift in the current research model, placing DNA-damaging agents in the forefront as likely mediators of testicular cancer induction,” said corresponding author Gunapala Shetty, PhD, assistant professor in the University of Texas MD Anderson Cancer Center’s (Houston, USA) department of experimental radiation oncology.

According to the American Cancer Society (Houston, TX, USA), more than 8,500 new instances of testicular cancer are diagnosed each year in the United States. During the past 50 years, the incidence has tripled in young Caucasian men worldwide. “This increase and the characteristics of germ cell tumors strongly suggest that fetal exposure to an environmental agent is responsible,” Dr. Shetty said. “However, the identification of any agent producing increases in testicular cancer has eluded scientists.”

Endocrine disruptors, compounds that alter the endocrine--or hormonal--system, have been widely believed to be the cause of testicular cancer, but there has been no evidence. Fetuses are particularly susceptible to even small amounts of the substances, which are known to cause developmental and cognitive issues.

This study started as an examination of endocrine disruptors as a possible cause of testicular cancer. Researchers separately tested two such compounds, the estrogen diethylstilbestrol (DES) and the anti-androgen flutamide. The endocrine disruptors were introduced into a mouse strain with a high spontaneous incidence of testicular cancer, which should make them more sensitive to cancer caused by environmental agents. However, the study’s findings revealed no increase in testicular cancer. However, when researchers gave small doses of radiation, which is a DNA-damaging agent, to female mice in the middle of their pregnancies, all the male offspring developed testicular cancer, compared to 45% of mice not exposed to radiation. Moreover, the tumors were more aggressive and had more sites of origin.

This study suggests that DNA-damaging agents, instead of endocrine disruptors, should be assessed as a factor in the increased prevalence of testicular cancer. “Although radiation exposure of pregnant females has been declining and is unlikely to be responsible for this increase, we intend to follow this up with studies of DNA-damaging chemicals found in cigarette smoke and air pollution, to which exposures of pregnant women have been increasing,” said study senior author Marvin Meistrich, PhD, professor in MD Anderson’s department of experimental radiation oncology.

This study opens the way for wide-ranging study, and researchers agree much work remains to be done. “A second class of DNA-damaging agents that we intend to study is chemotherapy drugs like cyclophosphamide, which are used to treat pregnant women with breast cancer,” Dr. Shetty said. “Studies at MD Anderson of the children of these women did not show increases in birth or developmental defects. However, we need to test these agents in our animal model since testicular cancer usually does not appear until early adulthood.”

Related Links:
University of Texas MD Anderson Cancer Center



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.